Catapult Therapeutics

Focus: Catapult Therapeutics is a Dutch biotech company founded in 2015 specializing in antibody therapy and cell-based immunotherapies targeting oncology and respiratory diseases. The company operates as a private pre-revenue biotech with a lean, innovation-focused pipeline.

Oncology Respiratory

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PRIVATE

Open Jobs

About Catapult Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Catapult Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

6 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

CAP-100

Lymphocytic Leukemia, Chronic

Phase 1

Clinical Trials (1)

NCT04704323CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia

Phase 1

Help build intelligence for Catapult Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage opportunity to shape immunotherapy programs across multiple modalities including TCR-transduced T cells and cell scaffolds in high-impact oncology indications
Focused pipeline with 6 active programs in Phase 1/2 stages across AML, CLL, MDS, and respiratory disease areas offering clinical advancement potential
Netherlands headquarters provides European biotech ecosystem access with potential for international career mobility and collaboration networks

Watch Out For

Zero active job postings and no disclosed employee count suggest minimal hiring activity or significant scale constraints for career growth
Pre-revenue private status with no disclosed funding data creates material uncertainty around cash runway and long-term stability
Early-stage pipeline (5 Phase 1 trials, 0 Phase 3 programs) means 7+ years minimum to regulatory approval with high clinical attrition risk

Generated by Claude from Catapult Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Cadaveric decellularised tracheal scaffold seeded with autologous mesenchymal cells

Tracheomalacia

Phase 1

Clinical Trials (1)

NCT02949414A Study to Assess the Safety, Tolerability and Potential Efficacy of a Tracheal Replacement Consisting of a Tissue-engineered Tracheal Scaffold With Seeded Mesenchymal Cells

Phase 1

Autologous WT1 TCR transduced T cells

Myelodysplastic Syndromes (MDS)

Phase 1/2

Clinical Trials (1)

NCT02550535A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML Patients

Phase 1/2

WT1 TCR-transduced T cells

Acute Myeloid Leukaemia

Phase 1/2

Clinical Trials (1)

NCT01621724WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study

Phase 1/2

BPF-001

Bronchopleural Fistula

Phase 1/2

Clinical Trials (1)

NCT04435249ENgineered Tissue Repair of BronchopleUral FiSTula

Phase 1/2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2015

Portfolio: 5 clinical trials

Top TAs: Oncology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

2 pipeline

Marketed

Pipeline